Personalis, Inc. PSNL
Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. Our testing services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and clinical trials. We also provide whole exome sequencing services for other diagnostic companies and whole genome sequencing services for population sequencing initiatives.
We perform our testing services in a large-scale, high-quality, Clinical Laboratory Improvement Amendments of 1988 ("CLIA") certified and College of American Pathologists ("CAP") accredited, laboratory located in our 100,000 square foot headquarters in Fremont, California. We were incorporated under the laws of the state of Delaware in 2011 under the name Personalis, Inc. and became a publicly-traded company in 2019.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.6M | $84.6M | $73.5M | $65.0M | $85.5M | $78.6M | $65.2M | $37.8M | $9.4M | — |
| Cost of revenue | $53.9M | $57.8M | $55.3M | $51.7M | $53.8M | $58.5M | $43.1M | $26.0M | $11.7M | — |
| Gross profit | $15.8M | $26.8M | $18.2M | $13.3M | $31.7M | $20.1M | $22.1M | $11.8M | -$2.3M | — |
| R&D | $50.3M | $48.9M | $64.8M | $64.9M | $49.3M | $28.6M | $22.4M | $14.3M | $9.9M | — |
| SG&A | $53.6M | $46.2M | $49.7M | $64.0M | $47.7M | $33.7M | $22.1M | $11.3M | $9.9M | — |
| Total operating expenses | $157.7M | $152.9M | $183.4M | $180.6M | $150.8M | $120.8M | $87.6M | $51.5M | $31.6M | — |
| Operating income | -$88.1M | -$68.3M | -$109.9M | -$115.5M | -$65.4M | -$42.1M | -$22.4M | -$13.8M | -$22.2M | — |
| Interest expense | $205.0K | $24.0K | $110.0K | $201.0K | $184.0K | $2.0K | $1.1M | $1.9M | $1.3M | — |
| Pre-tax income | -$81.2M | -$81.3M | -$108.2M | -$113.3M | -$65.2M | -$41.2M | -$25.1M | -$19.9M | -$23.6M | — |
| Income tax | $21.0K | $18.0K | $83.0K | $40.0K | $14.0K | $57.0K | $9.0K | $7.0K | $5.0K | — |
| Net income | -$81.3M | -$81.3M | -$108.3M | -$113.3M | -$65.2M | -$41.3M | -$25.1M | -$19.9M | -$23.6M | — |
| EPS, basic | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | — | — | — | — |
| EPS, diluted | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | -1.39 | -6.49 | -7.78 | — |
| Shares, diluted (wtd. avg.) | $89.2M | $59.3M | $48.2M | $45.7M | $43.9M | $34.4M | $18.0M | $3.1M | $3.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $124.2M | $91.4M | $57.0M | $89.1M | $105.6M | $68.5M | $55.0M | $19.7M | — | — |
| Short-term investments | $115.7M | $93.6M | $57.2M | $78.5M | $181.5M | $134.8M | $73.2M | — | — | — |
| Receivables | $16.2M | $8.1M | $17.7M | $16.6M | $18.5M | $6.3M | $3.3M | $4.5M | — | — |
| Total current assets | $268.0M | $203.0M | $146.7M | $199.7M | $318.2M | $220.7M | $139.6M | $29.6M | — | — |
| Property, plant and equipment | $44.8M | $48.3M | $57.4M | $61.9M | $19.6M | $11.8M | $14.1M | $11.5M | — | — |
| Total assets | $334.2M | $270.3M | $225.1M | $292.7M | $396.5M | $244.8M | $157.3M | $41.7M | — | — |
| Accounts payable | $13.0M | $6.4M | $14.9M | $12.9M | $9.2M | $8.3M | $7.3M | $6.6M | — | — |
| Short-term debt | — | — | — | — | — | — | — | $5.0M | — | — |
| Total current liabilities | $39.6M | $31.1M | $47.2M | $33.1M | $31.3M | $40.6M | $50.0M | $57.9M | — | — |
| Total liabilities | $73.0M | $67.3M | $95.7M | $74.6M | $86.2M | $49.9M | $50.6M | $58.7M | — | — |
| Retained earnings | -$631.3M | -$550.0M | -$468.7M | -$360.4M | -$247.1M | -$181.9M | -$140.6M | -$115.5M | — | — |
| Total equity | $261.2M | $203.0M | $129.4M | $218.1M | $310.3M | $194.9M | $106.7M | -$106.4M | -$92.6M | -$69.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$74.9M | -$45.1M | -$56.3M | -$70.2M | -$70.8M | -$42.7M | -$18.1M | $5.6M | $290.0K | — |
| Depreciation and amortisation | $10.0M | $10.9M | $11.3M | $8.4M | $6.0M | $5.8M | $4.7M | $3.1M | $1.2M | — |
| Stock-based compensation | $9.4M | $10.7M | $14.1M | $19.4M | $14.4M | $8.2M | $4.9M | $1.3M | $753.0K | — |
| Capital expenditure | $4.5M | $1.6M | $10.9M | $49.9M | $11.1M | $3.2M | $8.4M | $7.9M | $5.2M | — |
| Investing cash flow | -$22.6M | -$35.1M | $13.1M | $52.5M | -$60.1M | -$65.1M | -$81.6M | -$7.9M | -$5.2M | — |
| Financing cash flow | $130.3M | $114.7M | $11.0M | $1.4M | $169.7M | $121.3M | $134.9M | -$591.0K | $16.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-076615.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $47.31B | — | 35.9% |
| LH | LABCORP HOLDINGS INC. | $26.51B | 31.3x | 7.2% |
| DGX | QUEST DIAGNOSTICS INC | $26.17B | 27.1x | 11.8% |
| GH | Guardant Health, Inc. | $21.66B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $7.08B | — | 97.0% |
| RDNT | RadNet, Inc. | $5.80B | — | 11.5% |
| CELC | Celcuity Inc. | $4.68B | — | — |
| BLLN | BillionToOne, Inc. | $4.61B | 709.9x | 100.0% |